Adeola O Adebisi

Dr. Adeola O Adebisi

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
ZBZaheer Babar
Zaheer Babar
SRSara Ramzan
Sara Ramzan
FEFaris El-Dahiyat
Faris El-Dahiyat
ITIlias Tachmazidis
Ilias Tachmazidis
AAAdeola O Adebisi
Adeola O Adebisi
SHSyed Shahzad Hasan
Syed Shahzad Hasan
Background: One third of the world population does not have access to essential medicines. Diabetes require a long-term therapy, which incurs significant health care cost and thus impact access and affordability. This study aims to assess the availability, prices, and affordability of four essential medicines used to treat diabetes in private primary care pharmacies in 17 countries. Methods: Data on affordability, availability, and prices of four essential diabetes medicines from 51 primary care pharmacies across 17 countries were obtained using a variation of the World Health Organization/Health Action International (WHO/HAI) methodology. The surveyed countries were Oman, Qatar, Saudi Arabia, United Arab Emirates, China, Jordan, Russia, Armenia, Bangladesh, Egypt, Georgia, India, Pakistan, Sri Lanka, Afghanistan, Nepal, and Tanzania. International reference prices and daily income of the lowest-paid unskilled government workers were used as comparators. The prices were converted into US$ using both foreign exchange rates and purchasing power parity. We compared patterns of affordability and availability and prices of innovator brand (IB) and lowest priced generic (LPG) of diabetes medicines by WHO regional groupings and by country level. Results: Lowest priced generic of metformin 500 mg had the highest total mean availability (≥80%) among all the surveyed medicines. The total mean availability of insulin 100 IU/ml was only 36.21% (IBs and LPGs), where IB was more frequently available than LPG (50% vs. 26%) across 17 surveyed countries. Patients would have to spend more to procure 1-month’s supply of IB of insulin in low-income than patients in high-income countries (no. of day’s wages: 2.37 vs. 0.46, p = 0.038). For the majority of the surveyed countries the median price-ratio was less than 3. The highest PPP-adjusted prices for 30-day treatment with IB of insulin 100 IU/ml and metformin 500 mg were highest in Bangladesh ($80.21) and Tanzania ($4334.17), respectively. Conclusion: Availability of generic form of insulin is poor; IB of insulin was more affordable in high-income countries than low-income countries. Most of the LPGs was reasonably priced and affordable to the lowest-paid unskilled worker.

10 December 2014 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
AAAdeola O Adebisi
Adeola O Adebisi
PLPeter Laity
Peter Laity
Barbara ConwayBarbara Conway
Barbara Conway

1 August 2014 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AAAdeola O Adebisi
Adeola O Adebisi
Barbara ConwayBarbara Conway
Barbara Conway

11 March 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
SASalah Alghareeb
Salah Alghareeb
Kofi Asare-AddoKofi Asare-Addo
Kofi Asare-Addo
Barbara ConwayBarbara Conway
Barbara Conway
AAAdeola O Adebisi
Adeola O Adebisi

4 July 2011 in Journal of Microencapsulation
Verified
Journal Article
Closed access
PDF file
AAAdeola O Adebisi
Adeola O Adebisi
Barbara ConwayBarbara Conway
Barbara Conway
Many strategies have been proposed to explore the possibility of exploiting gastroretention for drug delivery. Such systems would be useful for local delivery, for drugs that are poorly soluble at higher pH or primarily absorbed from the proximal small intestine. Generally, the requirements of such strategies are that the vehicle maintains controlled drug release and exhibits prolonged residence time in the stomach. Despite widespread reporting of technologies, many have an inherent drawback of variability in transit times. Microparticulate systems, capable of distributing widely through the gastrointestinal tract, can potentially minimise this variation. While being retained in the stomach, the drug content is released slowly at a desired rate, resulting in reduced fluctuations in drug levels. This review summarises the promising role of microencapsulation in this field, exploring both floating and mucoadhesive microparticles and their application in the treatment of Helicobacter pylori, highlighting the clinical potential of eradication of this widespread infection.

15 January 2025 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Open access
SASalah Alghareeb
Salah Alghareeb
IEIfeoma Ekenna
Ifeoma Ekenna
KAKofi Asare-Addo
Kofi Asare-Addo
BCBarbara R. Conway
Barbara R. Conway
AAAdeola O Adebisi
Adeola O Adebisi